Spero Therapeutics, Inc.
SPRO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $55,659 | $77,474 | $65,022 | $494,641 |
| - Cash | $52,889 | $76,333 | $109,107 | $112,584 |
| + Debt | $4,297 | $5,543 | $6,647 | $7,335 |
| Enterprise Value | $7,067 | $6,684 | -$37,438 | $389,392 |
| Revenue | $47,977 | $103,781 | $48,579 | $3,070 |
| % Growth | -53.8% | 113.6% | 1,482.4% | – |
| Gross Profit | -$48,780 | $52,341 | $48,579 | $3,070 |
| % Margin | -101.7% | 50.4% | 100% | 100% |
| EBITDA | -$72,482 | $27,154 | -$42,941 | -$87,170 |
| % Margin | -151.1% | 26.2% | -88.4% | -2,839.4% |
| Net Income | -$68,566 | $22,806 | -$46,415 | -$89,756 |
| % Margin | -142.9% | 22% | -95.5% | -2,923.6% |
| EPS Diluted | -1.27 | 0.43 | -1.23 | -2.91 |
| % Growth | -395.3% | 135% | 57.7% | – |
| Operating Cash Flow | -$23,444 | -$32,995 | -$7,731 | -$64,347 |
| Capital Expenditures | $0 | $0 | $0 | $64,347 |
| Free Cash Flow | -$23,444 | -$32,995 | -$7,731 | $0 |